Home LiteratureArticle Details
PMID: 30018736 Published · epublish English Journal Article

A multiomics analysis of S100 protein family in breast cancer.

Oncotarget ·Vol. 9 ·No. 49 ·2018-06-26 ·Pages 29064-29081

Cancemi P, Buttacavoli M, Di Cara G, Albanese NN, Bivona S, Pucci-Minafra I, Feo S

Abstract

The S100 gene family is the largest subfamily of calcium binding proteins of EF-hand type, expressed in tissue and cell-specific manner, acting both as intracellular regulators and extracellular mediators. There is a growing interest in the S100 proteins and their relationships with different cancers because of their involvement in a variety of biological events closely related to tumorigenesis and cancer progression. However, the collective role and the possible coordination of this group of proteins, as well as the functional implications of their expression in breast cancer (BC) is still poorly known. We previously reported a large-scale proteomic investigation performed on BC patients for the screening of multiple forms of S100 proteins. Present study was aimed to assess the functional correlation between protein and gene expression patterns and the prognostic values of the S100 family members in BC. By using data mining, we showed that S100 members were collectively deregulated in BC, and their elevated expression levels were correlated with shorter survival and more aggressive phenotypes of BC (basal like, HER2 enriched, ER-negative and high grading). Moreover a multi-omics functional network analysis highlighted the regulatory effects of S100 members on several cellular pathways associated with cancer and cancer progression, expecially immune response and inflammation. Interestingly, for the first time, a pathway analysis was successfully applied on different omics data (transcriptomics and proteomics) revealing a good convergence between pathways affected by S100 in BC. Our data confirm S100 members as a promising panel of biomarkers for BC prognosis.

Keywords
S100 proteins breast cancer expression analysis pathway analysis proteomics
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Cancemi Patrizia
Department of Biological Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy. | Center of Experimental Oncobiology (C.OB.S.), La Maddalena Hospital III Level Oncological Dept., Palermo, Italy. | Advanced Technologies Network Center (ATeN), University of Palermo, Palermo, Italy.
Buttacavoli Miriam
Department of Biological Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy.
Di Cara Gianluca
Center of Experimental Oncobiology (C.OB.S.), La Maddalena Hospital III Level Oncological Dept., Palermo, Italy.
Albanese Nadia Ninfa
Center of Experimental Oncobiology (C.OB.S.), La Maddalena Hospital III Level Oncological Dept., Palermo, Italy.
Bivona Serena
Advanced Technologies Network Center (ATeN), University of Palermo, Palermo, Italy.
Pucci-Minafra Ida
Center of Experimental Oncobiology (C.OB.S.), La Maddalena Hospital III Level Oncological Dept., Palermo, Italy.
Feo Salvatore
Department of Biological Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy. | Advanced Technologies Network Center (ATeN), University of Palermo, Palermo, Italy. | Institute of Biomedicine and Molecular Immunology, CNR, Palermo, Italy.
Conflict of Interest

CONFLICTS OF INTEREST Authors declare no conflicts of interest.

References (61)
61 references, click to expand
  1. Expression of S100A11 is a Prognostic Factor for Disease-free Survival and Overall Survival in Patients With High-grade Serous Ovarian Cancer.
    Appl Immunohistochem Mol Morphol. 2017 Feb;25(2):110-116 PMID: 26574635
  2. Retrospective Proteomic Screening of 100 Breast Cancer Tissues.
    Proteomes. 2017 Jul 07;5(3): PMID: 28686225
  3. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer.
    Breast Cancer Res Treat. 2009 Mar;114(1):47-62 PMID: 18373191
  4. A contribution to breast cancer cell proteomics: detection of new sequences.
    Proteomics. 2002 Jul;2(7):919-27 PMID: 12124937
  5. Anticancer activity of biogenerated silver nanoparticles: an integrated proteomic investigation.
    Oncotarget. 2017 Dec 23;9(11):9685-9705 PMID: 29515763
  6. GOBO: gene expression-based outcome for breast cancer online.
    PLoS One. 2011 Mar 21;6(3):e17911 PMID: 21445301
  7. The value of calprotectin S100A8/A9 complex as a biomarker in colorectal cancer: A systematic review.
    J BUON. 2016 Jul-Aug;21(4):859-866 PMID: 27685906
  8. S100 proteins in cancer.
    Nat Rev Cancer. 2015 Feb;15(2):96-109 PMID: 25614008
  9. Differential occurrence of S100A7 in breast cancer tissues: a proteomic-based investigation.
    Proteomics Clin Appl. 2012 Aug;6(7-8):364-73 PMID: 22641350
  10. Leukocyte-derived koebnerisin (S100A15) and psoriasin (S100A7) are systemic mediators of inflammation in psoriasis.
    J Dermatol Sci. 2015 Sep;79(3):214-21 PMID: 26055798
  11. Pre-metastatic niches: organ-specific homes for metastases.
    Nat Rev Cancer. 2017 May;17(5):302-317 PMID: 28303905
  12. Cell death-associated molecular-pattern molecules: inflammatory signaling and control.
    Mediators Inflamm. 2014;2014:821043 PMID: 25140116
  13. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection.
    Nat Immunol. 2005 Jan;6(1):57-64 PMID: 15568027
  14. Differential proteomic and phenotypic behaviour of papillary and anaplastic thyroid cell lines.
    J Proteomics. 2013 Sep 2;90:115-25 PMID: 23385357
  15. Overexpression of S100A14 in human serous ovarian carcinoma.
    Oncol Lett. 2016 Feb;11(2):1113-1119 PMID: 26893702
  16. STRING v10: protein-protein interaction networks, integrated over the tree of life.
    Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52 PMID: 25352553
  17. Chromosomal mapping, differential origin and evolution of the S100 gene family.
    Genet Sel Evol. 2008 Jul-Aug;40(4):449-64 PMID: 18558076
  18. Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer.
    Int J Oncol. 2016 Mar;48(3):975-82 PMID: 26783118
  19. S100 protein in breast tumor.
    Indian J Cancer. 2014 Mar;51 Suppl 3:e67-71 PMID: 25818737
  20. Breast cancer cells exhibit selective modulation induced by different collagen substrates.
    Connect Tissue Res. 2008;49(3):252-6 PMID: 18661354
  21. Expanding the protein catalogue in the proteome reference map of human breast cancer cells.
    Proteomics. 2006 Apr;6(8):2609-25 PMID: 16526084
  22. Hallmarks of cancer: the next generation.
    Cell. 2011 Mar 4;144(5):646-74 PMID: 21376230
  23. Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion.
    BMC Cancer. 2015 Feb 13;15:53 PMID: 25884418
  24. ONCOMINE: a cancer microarray database and integrated data-mining platform.
    Neoplasia. 2004 Jan-Feb;6(1):1-6 PMID: 15068665
  25. In vitro phenotypic, genomic and proteomic characterization of a cytokine-resistant murine β-TC3 cell line.
    PLoS One. 2012;7(2):e32109 PMID: 22393382
  26. The role of S100 genes in breast cancer progression.
    Tumour Biol. 2011 Jun;32(3):441-50 PMID: 21153724
  27. S100A4 in cancer progression and metastasis: A systematic review.
    Oncotarget. 2017 May 19;8(42):73219-73239 PMID: 29069865
  28. Breast cancer statistics, 2013.
    CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62 PMID: 24114568
  29. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
    Sci Signal. 2013 Apr 02;6(269):pl1 PMID: 23550210
  30. Distinct prognostic values of S100 mRNA expression in breast cancer.
    Sci Rep. 2017 Jan 04;7:39786 PMID: 28051137
  31. Autoimmune pancreatitis results from loss of TGFbeta signalling in S100A4-positive dendritic cells.
    Gut. 2009 Sep;58(9):1267-74 PMID: 19625278
  32. Calgranulin C has filariacidal and filariastatic activity.
    Infect Immun. 1999 Dec;67(12):6631-6 PMID: 10569784
  33. Pro-inflammatory S100 proteins are associated with glomerulonephritis and anti-dsDNA antibodies in systemic lupus erythematosus.
    Lupus. 2017 Feb;26(2):139-149 PMID: 27407135
  34. Role of S100A1 in hypoxia-induced inflammatory response in cardiomyocytes via TLR4/ROS/NF-κB pathway.
    J Pharm Pharmacol. 2015 Sep;67(9):1240-50 PMID: 25880347
  35. Increased expression of S100A6 promotes cell proliferation in gastric cancer cells.
    Oncol Lett. 2017 Jan;13(1):222-230 PMID: 28123545
  36. The biochemistry and regulation of S100A10: a multifunctional plasminogen receptor involved in oncogenesis.
    J Biomed Biotechnol. 2012;2012:353687 PMID: 23118506
  37. Psoriasin, a multifunctional player in different diseases.
    Curr Protein Pept Sci. 2014;15(8):836-42 PMID: 25466546
  38. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis.
    Arthritis Res Ther. 2009;11(2):R39 PMID: 19284577
  39. Up-Regulation of S100A11 in Lung Adenocarcinoma - Its Potential Relationship with Cancer Progression.
    PLoS One. 2015 Nov 06;10(11):e0142642 PMID: 26544866
  40. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.
    Breast Cancer Res Treat. 2016 Dec;160(3):439-446 PMID: 27744485
  41. Certainty of S100 from Physiology to Pathology.
    J Clin Diagn Res. 2016 Jun;10(6):ZE10-5 PMID: 27504432
  42. Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.
    Anticancer Res. 2013 Feb;33(2):489-503 PMID: 23393341
  43. Large-scale proteomic identification of S100 proteins in breast cancer tissues.
    BMC Cancer. 2010 Sep 03;10:476 PMID: 20815901
  44. Nutritional Immunity: S100 Proteins at the Host-Pathogen Interface.
    J Biol Chem. 2015 Jul 31;290(31):18991-8 PMID: 26055713
  45. Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence.
    Nat Med. 2017 Nov;23(11):1319-1330 PMID: 28967919
  46. Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis.
    Arthritis Res Ther. 2017 Apr 26;19(1):79 PMID: 28446208
  47. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
    Cancer Discov. 2012 May;2(5):401-4 PMID: 22588877
  48. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Inflamm Bowel Dis. 2015 Feb;21(2):331-6 PMID: 25625487
  49. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles.
    Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 PMID: 11390274
  50. S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers.
    PLoS One. 2015 Dec 18;10(12):e0145418 PMID: 26682543
  51. S100 proteins and their influence on pro-survival pathways in cancer.
    Biochem Cell Biol. 2004 Aug;82(4):508-15 PMID: 15284904
  52. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis.
    Cancer Res. 2001 Nov 1;61(21):7999-8004 PMID: 11691825
  53. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
    Int J Clin Exp Pathol. 2015 Oct 01;8(10):13284-8 PMID: 26722531
  54. Innate immunity and antimicrobial defense systems in psoriasis.
    Clin Dermatol. 2007 Nov-Dec;25(6):616-24 PMID: 18021900
  55. A review of the S100 proteins in cancer.
    Eur J Surg Oncol. 2008 Apr;34(4):357-64 PMID: 17566693
  56. Proteomic profiling of 13 paired ductal infiltrating breast carcinomas and non-tumoral adjacent counterparts.
    Proteomics Clin Appl. 2007 Jan;1(1):118-29 PMID: 21136615
  57. New protein clustering of breast cancer tissue proteomics using actin content as a cellularity indicator.
    J Proteome Res. 2008 Apr;7(4):1412-8 PMID: 18284189
  58. Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14).
    J Infect Dis. 2000 Oct;182(4):1272-5 PMID: 10979933
  59. Multiple changes induced by fibroblasts on breast cancer cells.
    Connect Tissue Res. 2010 Apr;51(2):88-104 PMID: 20001846
  60. S100 protein family in human cancer.
    Am J Cancer Res. 2014 Mar 01;4(2):89-115 PMID: 24660101
  61. Immunohistochemical characteristics of basal-like breast cancer.
    Contemp Oncol (Pozn). 2016;20(6):436-443 PMID: 28239279
Article Info
Journal
Oncotarget
Abbr.
Oncotarget
ISSN
1949-2553
Published
2018-06-26
Epub
2018-00-26
Pages
29064-29081
Language
English
Region
United States
NLM ID
101532965
PMCID
PMC6044374
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]